Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Haemonetics Corporation (HAE)

NYQ · Medical Devices

$82.54+2.63 (+3.29%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$3.75B
P/E (TTM)
38.93
EPS
$2.12
Div Yield
52W Range
$47.32–$87.32
Beta
0.52

Company overview

Next earnings: 2026-08-06(9d)

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Peers in Medical Devices

All in industry →

Recent press releases

Haemonetics Corporation has not issued a press release in this window.

SEC filings

All filings →

Haemonetics Corporation has not filed an SEC document in this window.

Haemonetics Corporation has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
5,820,954 sh-3.3%
3,163,104 sh+48.6%
4,761,135 sh-1.5%
3,865,676 sh+5.3%
1,264,271 sh+3148.4%
1,309,132 sh+367.7%
1,351,814 sh+132.0%

People at Haemonetics Corporation

All people →

Quarterly financials

Full financials →
Revenue trend
12/24
$144.0M
NI $37.5M
06/25
$51.8M
NI $34.0M
09/25
$327.3M
NI $38.7M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $0.81
Prior: $0.70
Revenue sparkline